AbCellera Biologics Inc. has announced the initiation of the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635, a potential first-in-class non-hormonal treatment for moderate-to-severe vasomotor symptoms associated with menopause. The Phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial that will evaluate the efficacy of ABCL635 in reducing the frequency and severity of vasomotor symptoms in 80 postmenopausal women. The transition to Phase 2 follows an interim review of safety, tolerability, and pharmacodynamic data from the Phase 1 portion of the study. Top-line clinical results for both phases are expected to be presented in the third quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112396118) on January 12, 2026, and is solely responsible for the information contained therein.